Capecitabine-induced, nonneutropenic enterocolitis.
Department of Internal Medicine, Section of Hematology and Medical Oncology, CancerCare Manitoba, University of Manitoba, 675 McDermot Avenue, Winnipeg, MB, R3E 0V9, Canada. vallerie.gordon@cancercare.mb.ca
Vallerie L
VL
Gordon
Gary A
GA
Harding
Piotr
P
Czaykowski
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy*; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000069287:Capecitabine; D002430:Cecal Neoplasms / Q000150:complications / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D004760:Enterocolitis / Q000139:chemically induced* / Q000473:pathology; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
Eur J Cancer. 2004 May;40(7):939-50
15093568
Cancer Chemother Pharmacol. 2010 Jan;65(2):403-6
19795123
Cancer. 1997 Aug 15;80(4):656-60
9264347
J Clin Oncol. 2008 Jul 10;26(20):3411-7
18612156
Anticancer Drugs. 2006 Aug;17(7):865-8
16926637
N Engl J Med. 2005 Jun 30;352(26):2696-704
15987918
Eur J Haematol. 2005 Jul;75(1):1-13
15946304
Ann Oncol. 2007 Mar;18(3):607-8
17170015
Expert Opin Drug Saf. 2004 Mar;3(2):89-92
15006714
J Clin Oncol. 2001 Apr 15;19(8):2282-92
11304782